TIM-3 as a therapeutic target for malignant stem cells in acute myelogenous leukemia

研究成果: Contribution to journalArticle

22 引用 (Scopus)

抜粋

Acute myeloid leukemia (AML) originates from self-renewing leukemic stem cells (LSCs), an ultimate therapeutic target for AML. Recent studies have shown that many AML LSC-specific surface antigens could be such candidates. T cell immunoglobulin mucin-3 (TIM-3) is expressed on LSCs in most types of AML, except for acute promyelocytic leukemia, but not on normal hematopoietic stem cells (HSCs). In mouse models reconstituted with human AML LSCs or human hematopoietic stem cells, a human TIM-3 mouse IgG2a antibody with complement-dependent and antibody-dependent cellular cytotoxic activities eradicates AML LSCs in vivo but does not affect normal human hematopoiesis. Thus, TIM-3 is one of the promising targets to eradicate AML LSCs.

元の言語英語
ページ(範囲)118-123
ページ数6
ジャーナルAnnals of the New York Academy of Sciences
1266
発行部数1
DOI
出版物ステータス出版済み - 8 2012

All Science Journal Classification (ASJC) codes

  • Neuroscience(all)
  • Biochemistry, Genetics and Molecular Biology(all)
  • History and Philosophy of Science

フィンガープリント TIM-3 as a therapeutic target for malignant stem cells in acute myelogenous leukemia' の研究トピックを掘り下げます。これらはともに一意のフィンガープリントを構成します。

  • これを引用